Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Leuk Lymphoma. 2017 Aug 7;59(4):837–843. doi: 10.1080/10428194.2017.1361027

Figure 1.

Figure 1

Cumulative incidence of (A) overall survival, (B) relapse rate, (C) relapse-free survival, and (D) non-relapse mortality, of patients with (acute myelogenous leukemia) AML undergoing hematopoietic stem cell transplantation (HSCT). Black line represents Bu/Cy conditioning, red line represents Flu/Mel conditioning. p values as indicated.